US Stock MarketDetailed Quotes
NEUP Neuphoria Therapeutics
- 6.630
- +3.593+118.29%
Close Dec 24 13:00 ET
- 5.020
- -1.610-24.28%
Post 16:59 ET
10.79MMarket Cap-0.43P/E (TTM)
10.500High3.750Low1.18MVolume10.200Open3.037Pre Close8.26MTurnover84.30%Turnover RatioLossP/E (Static)1.63MShares18.00052wk High0.63P/B9.24MFloat Cap2.12452wk Low--Dividend TTM1.39MShs Float264.000Historical High--Div YieldTTM222.24%Amplitude2.112Historical Low7.023Avg Price1Lot Size
About Neuphoria Therapeutics Company
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
Company Profile
SymbolNEUP
Company NameNeuphoria Therapeutics
CEODr. Spyros Papapetropoulos, PhD
MarketNASDAQ
Employees24
Fiscal Year Ends06-30
Websitehttps://www.bionomics.com.au
Company Executives
- Name
- Position
- Salary
- Dr. Spyros Papapetropoulos, PhD
- Director, President and Chief Executive Officer
- 919.77K
- Timothy M. Cunningham
- Chief Financial Officer
- --
- Adrian Hinton
- Financial Controller and Principal Accounting Officer
- 299.55K
- Liz Doolin
- Vice President, Clinical Development
- 357.03K
- Alan Fisher
- Chairman of the Board
- 87.00K
- Dr. Jane Ryan, PhD
- Independent Director
- 86.72K
- Peter Miles Davies
- Independent Director
- 77.00K
- David Wilson
- Independent Director
- 87.00K
Heat List
US
Overall
Symbol
Price
% Chg
No Data
